NOVONIX (NVX) CEO reports 3.7M performance rights over ordinary shares

Rhea-AI Filing Summary

NOVONIX Ltd filed an initial insider ownership report for Chief Executive Officer Michael O'Kronley. The filing shows he holds performance rights that can be converted into 3,723,971 ordinary shares at an exercise price of $0.0000 per share, with these rights expiring on December 31, 2028. This is a holdings disclosure rather than a new buy or sell transaction.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Kronley Michael

(Last) (First) (Middle)

1029 WEST 19TH STREET

(Street)

CHATTANOOGA TN 37408

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
NOVONIX Ltd [ NVX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance rights	12/31/2027	12/31/2028	Ordinary shares	3,723,971	$0	D

Explanation of Responses:

Remarks:

Performance rights vest based on 3 year TSR performance subject to a revenue modifier.

	Suzanne Yeates	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does NOVONIX (NVX) CEO Michael O'Kronley report on this Form 3?

Michael O'Kronley reports his existing holdings of performance rights in NOVONIX. These rights are linked to ordinary shares and represent potential future equity, rather than a current stock purchase or sale in the market.

How many NOVONIX (NVX) shares are underlying the CEO’s performance rights?

The filing shows performance rights over 3,723,971 underlying ordinary shares. This figure reflects potential future share ownership if the rights convert, not current common stock already issued to the CEO.

What is the exercise price of Michael O'Kronley’s NOVONIX (NVX) performance rights?

The performance rights have an exercise price of $0.0000 per share. This means no cash payment is required upon conversion into ordinary shares, subject to the applicable vesting and performance conditions governing these rights.

When do NOVONIX (NVX) CEO Michael O'Kronley’s performance rights expire?

The performance rights expire on December 31, 2028. The filing also lists a related exercise date of December 31, 2027, indicating the period during which these rights may be converted into ordinary shares if conditions are met.

Does this NOVONIX (NVX) Form 3 show the CEO buying or selling shares?

No, this Form 3 records existing derivative holdings, not a trade. It identifies performance rights over ordinary shares held directly by the CEO, without reporting any open-market purchases or sales of NOVONIX common stock.